Optimization of approaches to the management of adult patients with severe atopic dermatitis: analysis of real clinical practice outcomes

• Main Authors: Daria S. Fomina (Author), Sofya A. Serdotetskova (Author), Anton A. Chernov (Author), Marina S. Lebedkina (Author), Asel Iu. Nurtazina (Author), Mirada K. Gadzhieva (Author), Olga A. Mukhina (Author), Elena N. Bobrikova (Author)
• Format: Book
• Published: ZAO "Consilium Medicum", 2021-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2075-1753; 2542-2170; 10.26442/20751753.2021.8.201115
• Keywords: atopic dermatitis; targeted biologic therapy; dupilumab; multimorbidity; bronchial asthma; phenotypes; Medicine (General); R5-920; Therapeutics. Pharmacology; RM1-950
• Source: Consilium Medicum, Vol 23, Iss 8, Pp 654-661 (2021)

Atopic dermatitis (AD) is a multifactorial genetically determined immune-mediated skin disease. It is difficult to treat and significantly affects patients quality of life. The development of an integrated approach focusing on atopic multimorbidity, implementation of validated control tools and distinction of clinical parameters specific for different phenotypes of severe forms of disease is especially relevant to patients resistant to standard therapy techniques. Dupilumab, a biologic, is approved for the treatment of the resistant group of patients with moderate to severe AD in the Russian Federation. Dupilumab inhibits the functions of two key cytokines of T2-mediated inflammation IL-4 and IL-13. The article presents personal experience of the authors concerning individual approach to the choice of therapy for the management of this cohort of patients in routine clinical practice. The disease aggravating criteria were determined, which are fundamental for the formation of individual patient portrait for the biologic (dupilumab) treatment for severe AD.